2142.HK Stock Analysis
21
Uncovered
Hbm Holdings Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. The company employs 365 full-time employees The company went IPO on 2020-12-10. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.